Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational botanical mixture combining extracts from the bark of *Guazuma ulmifolia* and the leaves/flowers of *Tecoma stans*. Developed by the Centro Universitario de Ciencias de la Salud at the University of Guadalajara, Mexico, it is being evaluated for the treatment of type 2 diabetes mellitus. The mixture, often referred to in the context of the GUATECO clinical trial, is administered orally as a 400 mg capsule containing 313.6 mg of *Guazuma ulmifolia* and 86.4 mg of *Tecoma stans*. Its mechanism of action involves the stimulation of glucose uptake in adipocytes and the inhibition of the alpha-glucosidase enzyme, which helps in reducing postprandial glucose levels. Clinical studies have demonstrated its potential to improve glycemic control, evidenced by significant reductions in fasting glucose, HbA1c, and waist circumference in patients with type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guazuma ulmifolia + tecoma stans.